Sanara MedTech (NASDAQ:SMTI) Announces Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Sanara MedTech (NASDAQ:SMTI) announced its earnings results on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07), Zacks reports. The company had revenue of $27.55 million during the quarter, compared to the consensus estimate of $27.90 million. Sanara MedTech had a negative net margin of 36.42% and a negative return on equity of 16.72%.

Here are the key takeaways from Sanara MedTech’s conference call:

• Revenue milestone: Sanara exceeded $100 million of net revenue in 2025 ($103.1M, +19% YoY) while maintaining a roughly 40-person field sales force, highlighting scalability of its hybrid commercial model.
• Profitability and cash generation improved: Full-year gross margin expanded to ~93% (~200 bps improvement), adjusted EBITDA rose to $17M (+86% YoY), and cash from operations was $6.8M versus $24K used in 2024.
• Distribution catalyst — BIASURGE won Vizient’s Innovative Technology contract effective Jan 1, 2026, providing access to ~1,800 facilities and a meaningful commercial runway for adoption.
• Forward visibility — management introduced and reaffirmed 2026 net revenue guidance of $116M–$121M (13%–17% growth) and Q1 revenue guidance of ~$26.7M–$27.2M, signaling confidence in near-term execution.
• Balance sheet and expense risks — cash was $16.6M while long-term debt increased to $46M, Q4 continuing-operations net loss was $1.1M, and operating expenses rose partly due to a $1.8M non-cash IP impairment, indicating leverage and near-term cost headwinds.

Sanara MedTech Price Performance

NASDAQ:SMTI opened at $16.34 on Thursday. The company has a quick ratio of 1.60, a current ratio of 1.80 and a debt-to-equity ratio of 7.34. The business’s 50-day moving average price is $20.23 and its 200 day moving average price is $24.61. Sanara MedTech has a 52-week low of $16.05 and a 52-week high of $35.95. The firm has a market cap of $145.43 million, a P/E ratio of -3.86 and a beta of 1.04.

Analysts Set New Price Targets

A number of analysts have commented on SMTI shares. Weiss Ratings restated a “sell (e+)” rating on shares of Sanara MedTech in a research report on Thursday, January 22nd. Zacks Research lowered shares of Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of Sanara MedTech in a report on Monday, January 26th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $36.00.

Hedge Funds Weigh In On Sanara MedTech

Several large investors have recently made changes to their positions in SMTI. BNP Paribas Financial Markets raised its holdings in shares of Sanara MedTech by 351.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock worth $48,000 after purchasing an additional 1,171 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock worth $89,000 after buying an additional 3,155 shares in the last quarter. Bank of America Corp DE boosted its holdings in Sanara MedTech by 44.1% during the third quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock worth $101,000 after buying an additional 973 shares in the last quarter. Wells Fargo & Company MN grew its position in Sanara MedTech by 78.1% in the fourth quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock worth $78,000 after buying an additional 1,457 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Sanara MedTech by 14.9% in the first quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock worth $115,000 after buying an additional 483 shares during the last quarter. Institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.